Tiziana Life Sciences Ltd · NASDAQ:TLSA
Tiziana Life Sciences — Investor Presentation (2026)
19 slides from Tiziana Life Sciences's investor presentation, 2026
Slide 1: Intranasal Fully Human Anti-CD3 mAb (Foralumab) Therapy
Intranasal Fully Human Anti-CD3 mAb (“FORALUMAB”) Therapy to Enable Breakthroughs in Neuroinflammatory and Neurodegenerative Diseases Nasdaq: TLSA
Slide 2: Foralumab: Mechanism of Action
1 Foralumab: Intranasal Single dose Mechanism of Action1,2 Foralumab Patient inhales the antibody intranasally Binding of foralumab to the T-cell receptor complex in cervical lymph node Tregs are then created 2 Binding CD3/TCR complex BBB and activated Blood-Brain-Barrier Uptake T cell 3 These creat
Slide 3: Non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Slide 4: Non-Active Secondary Progressive Multiple Sclerosis is an Attractive Market
Non-Active Secondary Progressive Multiple Sclerosis is an Attractive Market Approximately 25% of There are currently no effective Relapsing Remitting MS treatments for (RRMS) patients are estimated Non-Active (non-relapsing) SPMS to progress to SPMS* Secondary Progressive Multiple Global Multiple Sc
Slide 5: Intranasal Foralumab Reduces Neuroinflammation
Intranasal Foralumab Reduces Neuroinflammation EA6 5
Slide 6: Improvement or Stabilization in all na-SPMS Expanded Access Patients
Improvement or Stabilization in all na-SPMS Expanded Access Patients • Clinical improvements or stabilization was reported across most of the group, as measured by Fatigue scores (MFIS) and EDSS • Fatigue scores improved in 11/14 patients • Clinically meaningful improvement in MFIS seen in 9/14 pati
Slide 7: Favourable Trends Seen in Stability of Disability and Improvements in Fatigue
Favourable Trends Seen in Stability of Disability and Clinically Meaningful Improvements in Fatigue. • EDSS Stabilization: Favorable trend toward disease stabilization (i.e., reduced Confirmed Disability Progression (CDP) • Fatigue Improvement: 64% of patients achieved a clinically meaningful improv
Slide 8: Non-Active Secondary Progressive MS: Phase 2a Study Design
Non-Active Secondary Progressive MS: Phase 2a Study Design: Intranasal Foralumab Dosing (n=48); Double-Blind, Placebo-Controlled Primary Endpoint Baseline at 3 Months of Each Cycle = 3 Weeks / 4 cycles x 3 = 12 weeks Screening Treatment Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
Slide 9: Multiple System Atrophy (MSA)
Multiple System Atrophy (MSA)
Slide 10: Multiple System Atrophy (MSA) Phase 2a Clinical Trial
Multiple System Atrophy (MSA) Phase 2a Clinical Trial MSA is a rapidly progressive neurological disorder. It is caused by degeneration or atrophy (shrinking) of nerve cells in several (or multiple) areas of the brain. Classified as Orphan FDA Approved IND Q3 disease by the FDA 2025 No FDA approved F
Slide 11: Early Symptomatic & Moderate Alzheimer's Disease (AD)
Early Symptomatic & Moderate Alzheimer’s Disease (AD)
Slide 12: Alzheimer's Disease Program is Advancing and Equally Exciting
Alzheimer’s Disease Program is Advancing and Equally Exciting Awarded $4 Million Grant from National Institutes of Health (NIH), National Institute on Aging to Study Anti-CD3 in Alzheimer’s Disease Letter to Proceed received for IND to conduct a Phase 2 study of intranasal foralumab in Alzheimer’s d
Slide 13: Moderate Alzheimer's Disease Expanded Access Study
Moderate Alzheimer’s Disease Expanded Access Study • 78-Year-Old Moderate Alzheimer’s patient treated for 3 months with intranasal foralumab • PET Scan shows significant reduction of microglia activity following 3 months of treatment • Data presented at AD/PD in April 2025 • Data Published in the Jo
Slide 14: Early Symptomatic Alzheimer's Disease: Phase 2a Study Design
Early Symptomatic Alzheimer’s Disease: Phase 2a Study Design: Intranasal Foralumab Dosing (n=32); Double-Blind, Placebo-Controlled, 2 Treatment Arms: 12 x 50mcg, 12 x 100mcg, 8 x Placebo. Primary Endpoint at 3 Months of Baseline Each Cycle = 3 Weeks / 4 cycles x 3 = 12 Week readout Screening Treatme
Slide 15: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Slide 16: ALS Phase 2 Study Supported by The ALS Association
ALS Phase 2 Study Supported by The ALS Association Grant Awarded from The ALS Association to Study Intranasal Foralumab in ALS patients in a 20 Patient, Dose Ranging, Phase 2 Clinical Trial Global Market size of $790m IND Filed March 2025 CARG of 5.8% from 2024-2030 Phase 2 trial planned to start H1
Slide 17: ALS: Phase 2a Study Design
ALS: Phase 2a Study Design: Intranasal Foralumab Dosing (n=24); Randomized, Placebo Controlled Trial Primary Endpoint Baseline Each Cycle = 3 Weeks / 4 cycles x 3 = 12 week readout / 4 cycles x 6 = 24 week readout at 6 Months of Screening Treatment Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 We
Slide 18: Intranasal Foralumab Pipeline
Intranasal Foralumab Pipeline Expanded Preclinical IND Phase 1 Access Phase 2 Phase 3 Program Non-Active Secondary Expecting Topline Progressive Multiple Data Sclerosis Phase 2 Study 2H 2026 Multiple System Atrophy Began dosing Aug (MSA) Phase 2 Study 2025 Alzheimer’s Disease (Mild) Began dosing Dec
Slide 19: Nasdaq: TLSA
US Headquarters (Boston) Tiziana Life Sciences Ltd. 535 Boylston Street, Floor 8 Boston, MA 02116 UK Headquarters (London) Tiziana Life Sciences plc 35a Albemarle Street London W1S 4JE Investors: +44 (0)207 495 2379 info@tizianalifesciences.com Nasdaq: TLSA